Literature DB >> 9282948

Brain and spinal cord distribution of biphalin: correlation with opioid receptor density and mechanism of CNS entry.

T J Abbruscato1, S A Thomas, V J Hruby, T P Davis.   

Abstract

Biphalin [(Tyr-D-Ala-Gly-Phe-NH)2] is a bivalent, opioid peptide containing two pharmacophores linked by a hydrazine bridge. When administered intracerebroventricularly, it has been shown to be more potent than morphine and etorphine at eliciting antinociception. Biphalin has also been shown to cross both the blood-brain and blood-cerebrospinal fluid barriers. To understand the basis of biphalin's potency, regional brain and spinal cord distribution studies with [125I-Tyr1]biphalin were performed 5, 20, and 40 min after intravenous bolus injections. A statistically greater amount of [125I-Tyr1]biphalin was detected in the nucleus accumbens compared with other brain regions (p < 0.05). This correlates with the high density of delta- and mu-opioid receptor mRNA and binding sites shown to be expressed in the nucleus accumbens. Also, a statistically greater amount of [125I-Tyr1] biphalin was detected in two other circumventricular organs, the choroid plexus and pituitary, when compared with other brain regions. These studies provide evidence that biphalin can reach not only brain sites, but also spinal sites to elicit antinociception. The overall CNS distribution of [125I-Tyr1]biphalin was decreased with naloxone, D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2, or naltrindole pretreatment, showing that biphalin detected in the brain and spinal cord is binding to delta- and mu-opioid receptors. Additional in situ brain perfusion experiments identified a saturable component contributing to CNS entry of [125I-Tyr1]biphalin, which could be described by Michaelis-Menten kinetics with a Km of 2.6 +/- 4.8 microM, Vmax of 14.6 +/- 2.89 pmol(-1) x min(-1) x g(-1), and Kd of 0.568 +/- 0.157 microl x min(-1) x g(-1). Brain entry of [125I-Tyr1]biphalin was sensitive to 2-aminobicyclo[2.2.1]heptane-2-carboxylic acid and L-phenylalanine, suggesting use of the large neutral amino acid carrier. This work provides evidence that biphalin is a promising, potent analgesic that has a unique mechanism for reaching both spinal and supraspinal opioid receptor sites.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9282948     DOI: 10.1046/j.1471-4159.1997.69031236.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  15 in total

1.  A molecular dynamics study on opioid activities of biphalin molecule.

Authors:  Jin-Yuan Hsieh; Tzen-Yuh Chiang; Jun-Liang Chen; Yun-Wen Chen; Hong-Chang Lin; Chi-Chuan Hwang
Journal:  J Mol Model       Date:  2010-12-23       Impact factor: 1.810

Review 2.  Development of neuropeptide drugs that cross the blood-brain barrier.

Authors:  Richard D Egleton; Thomas P Davis
Journal:  NeuroRx       Date:  2005-01

Review 3.  Opioid ligands with mixed mu/delta opioid receptor interactions: an emerging approach to novel analgesics.

Authors:  Subramaniam Ananthan
Journal:  AAPS J       Date:  2006-03-10       Impact factor: 4.009

Review 4.  CNS drug delivery: opioid peptides and the blood-brain barrier.

Authors:  Ken A Witt; Thomas P Davis
Journal:  AAPS J       Date:  2006-02-24       Impact factor: 4.009

Review 5.  Peptides at the blood brain barrier: Knowing me knowing you.

Authors:  Thomas P Davis; Thomas J Abbruscato; Richard D Egleton
Journal:  Peptides       Date:  2015-04-30       Impact factor: 3.750

6.  Biological active analogues of the opioid peptide biphalin: mixed α/β(3)-peptides.

Authors:  Adriano Mollica; Francesco Pinnen; Roberto Costante; Marcello Locatelli; Azzurra Stefanucci; Stefano Pieretti; Peg Davis; Josephine Lai; David Rankin; Frank Porreca; Victor J Hruby
Journal:  J Med Chem       Date:  2013-04-12       Impact factor: 7.446

7.  Novel cyclic biphalin analogue with improved antinociceptive properties.

Authors:  Adriano Mollica; Alfonso Carotenuto; Ettore Novellino; Antonio Limatola; Roberto Costante; Francesco Pinnen; Azzurra Stefanucci; Stefano Pieretti; Anna Borsodi; Reza Samavati; Ferenc Zador; Sándor Benyhe; Peg Davis; Frank Porreca; Victor J Hruby
Journal:  ACS Med Chem Lett       Date:  2014-07-14       Impact factor: 4.345

8.  Characterization of neuroprotective effects of biphalin, an opioid receptor agonist, in a model of focal brain ischemia.

Authors:  Li Yang; Kaushik Shah; Hezhen Wang; Vardan T Karamyan; Thomas J Abbruscato
Journal:  J Pharmacol Exp Ther       Date:  2011-08-19       Impact factor: 4.030

9.  In vitro and in vivo efficacy of a potent opioid receptor agonist, biphalin, compared to subtype-selective opioid receptor agonists for stroke treatment.

Authors:  Li Yang; Mohammad R Islam; Vardan T Karamyan; Thomas J Abbruscato
Journal:  Brain Res       Date:  2015-03-20       Impact factor: 3.252

10.  Tyr1-ψ[( Z)CF═CH]-Gly2 Fluorinated Peptidomimetic Improves Distribution and Metabolism Properties of Leu-Enkephalin.

Authors:  Ryan A Altman; Krishna K Sharma; Lian G Rajewski; Paul C Toren; Michael J Baltezor; Mohan Pal; Somnath N Karad
Journal:  ACS Chem Neurosci       Date:  2018-04-19       Impact factor: 4.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.